For research use only. Not for therapeutic Use.
VII-31(Cat No.:I015275)is a selective small-molecule inhibitor targeting the protein-protein interaction between p53 and murine double minute 2 (MDM2), a key pathway in cancer research. By blocking MDM2, VII-31 prevents the degradation of p53, allowing for the reactivation of p53’s tumor-suppressive functions, such as promoting cell cycle arrest and apoptosis in cancer cells. Its specificity for the p53-MDM2 interaction minimizes off-target effects, making it a promising candidate for targeted cancer therapies, especially in tumors with intact but inhibited p53. VII-31 serves as a valuable tool in developing precision oncology strategies.
Catalog Number | I015275 |
CAS Number | 2305757-96-2 |
Molecular Formula | C₂₃H₂₅NO₅S |
Purity | ≥95% |
Target | Apoptosis |
IUPAC Name | N-[(4-methoxyphenyl)methyl]-2-thiophen-2-yl-N-(3,4,5-trimethoxyphenyl)acetamide |
InChI | InChI=1S/C23H25NO5S/c1-26-18-9-7-16(8-10-18)15-24(22(25)14-19-6-5-11-30-19)17-12-20(27-2)23(29-4)21(13-17)28-3/h5-13H,14-15H2,1-4H3 |
InChIKey | CGVFRZMQURRQIE-UHFFFAOYSA-N |
SMILES | COC1=CC=C(C=C1)CN(C2=CC(=C(C(=C2)OC)OC)OC)C(=O)CC3=CC=CS3 |
Reference | [1]. Dong-Jun Fu, et al. Discovery of Novel Tertiary Amide Derivatives as NEDDylation Pathway Activators to Inhibit the Tumor Progression in Vitro and in Vivo. Eur J Med Chem. 2020 Apr 15;192:112153. |